It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Duloxetine in the treatment of chronic pain due to fibromyalgia and di
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14789

Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy



Review

(8362) Total Article Views


Authors: Alan Wright, Kyle E Luedtke, Chad VanDenBerg

Published Date December 2010 Volume 2011:4 Pages 1 - 10
DOI: http://dx.doi.org/10.2147/JPR.S12866

Alan Wright, Kyle E Luedtke, Chad VanDenBerg
Center for Clinical Research, Mercer University, Atlanta, Georgia, USA

Abstract: Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved by the US Food and Drug Administration for the treatment of fibromyalgia and painful diabetic neuropathy at doses of 60 mg daily. Duloxetine has been shown to significantly improve the symptoms of chronic pain associated with these disorders, as measured by the Fibromyalgia Impact Questionnaire, Brief Pain Inventory scores, the Clinical Global Impressions Scale, and other various outcome measures in several placebo-controlled, randomized, double-blind, multicenter studies. Symptom improvement generally began within the first few weeks, and continued for the duration of the study. In addition, the efficacy of duloxetine was found to be due to direct effects on pain symptoms rather than secondary to improvements in depression or anxiety. Adverse events including nausea, constipation, dry mouth, and insomnia, were mild and transient and occurred at relatively low rates. In conclusion, duloxetine, a selective inhibitor for the serotonin and norepinephrine transporters, is efficacious in the treatment of chronic pain associated with fibromyalgia or diabetic neuropathy, and has a predictable tolerability profile, with adverse events generally being mild to moderate.

Keywords: duloxetine, chronic pain, neuropathic pain, fibromyalgia, efficacy, safety


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: